Comparative analysis of efficacy between autoimplantation and intralesional MMR vaccine in viral warts
Phase 2
- Conditions
- Health Condition 1: - Health Condition 2: L088- Other specified local infections of the skin and subcutaneous tissue
- Registration Number
- CTRI/2024/02/062715
- Lead Sponsor
- KLEH Dr Prabhakar Kore Hospital and Medical Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Patients more than 12 years of age with multiple warts less than 10 in number who are willing to participate in the study
Exclusion Criteria
1)Single wart
2)Pregnant or planning pregnancy in the next three months
3)Lactating women
4)Patients with local dermatological condition
5)Patients with apparent infection, immunosuppression, or are on immunosuppressive drugs, asthma, allergic skin disorders, meningitis or convulsions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in size of wart assessed by VAS scoring systemTimepoint: Baseline,3 weeks, 6 weeks, 9 weeks, 12 weeks
- Secondary Outcome Measures
Name Time Method To assess adverse reactions in Inralesional Injection MMR & AutoimplantationTimepoint: Baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks